VYNE Projected Dividend Yield
Com Par $/VYNE Therapeutics Inc ( NASDAQ : VYNE )VYNE Therapeutics is a biopharmaceutical company that develops therapies for the treatment of immuno-inflammatory conditions. Co.'s primary program is VYN201, an administered pan-bromodomain and extra-terminal (BET) inhibitor to address diseases involving multiple inflammatory cell signaling pathways while providing low systemic exposure. Co.'s second program is VYN202, a BD2-selective oral small molecule BET inhibitor. VYN202 is in preclinical development for the treatment of immuno-inflammatory indications. FMX114 is Co.'s proprietary investigational combination gel formulation of tofacitinib and fingolimod that addresses both the source and cause of inflammation in atopic dermatitis. 20 YEAR PERFORMANCE RESULTS |
VYNE Dividend History Detail VYNE Dividend News VYNE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |